Market
First major medical journal to feature AALL1731 trial results by March 2025?
2
Resolution / Starting Odds
The New England Journal of Medicine • 25%
The Lancet • 25%
JAMA • 25%
Other • 25%
Published articles in major medical journals
Story
Amgen's BLINCYTO® Improves Survival in Pediatric B-Cell ALL: AALL1731 Results at ASH24
Dec 8, 2024, 02:04 PM
At the American Society of Hematology's (ASH) 2024 Annual Meeting (#ASH24), significant clinical trial results were presented, highlighting advancements in the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). A key study presented by the Children's Oncology Group (COG) revealed that the addition of blinatumomab, marketed as BLINCYTO® by Amgen, to induction chemotherapy significantly improved disease-free survival in children with standard-risk B-ALL. The full results of the AALL1731 trial demonstrated enhanced survival rates when blinatumomab was added to chemotherapy regimens for newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia.
View original story
Similar markets
Yes • 50%
No • 50%
NEJM • 25%
The Lancet • 25%
JAMA • 25%
BMJ • 25%
Nature • 25%
New England Journal of Medicine • 25%
The Lancet • 25%
Other • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Universal gene therapy • 33%
Mutation-specific gene therapy • 33%
No approval • 34%
No improvement • 25%
Worsening condition • 25%
Moderate improvement • 25%
Significant improvement • 25%
Positive results • 25%
Negative results • 25%
Trial halted • 25%
Inconclusive results • 25%
University of Southern California • 25%
Other • 25%
Nucleic Acid Observatory • 25%
Prime Intellect • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%